Fig. 4
Somatic gene alterations identified in acquired RET+ patients who exhibit resistance to EGFR-TKIs. a Genomic landscape of somatic gene alterations in patients with acquired RET fusions (N = 71). Grouping of patients is based on EGFR-TKI treatment regimens. Each column represents one patient. The clinical characteristics of each patient are shown on the top. The percentage on the right shows the mutation frequency of each gene. Grouping of second-line PFS was in line with the results of the AURA3 study (mPFS duration of 10.1 months) [43]. b Kaplan–Meier estimates of PFS in acquired RET+ patients who previously received 2L 3rd-G EGFR-TKI therapy (N = 49, see Additional file 5: Fig. S4b for patient assortment) with or without bypass pathway mutations (activating mutations in KRAS and PIK3CA, copy-number gain in ERBB2 and MET, fusions in ALK and NTRK). c Kaplan–Meier estimates of PFS comparing patients with or without double-mutated RB1 and TP53 genes. d Kaplan–Meier estimates of PFS comparing patients with or without ERBB2 amplification. e The incidence of RET fusions in EGFR-mutant NSCLC patients previously treated with different EGFR-TKIs